

We want to save patients with severe cancer and autoimmune diseases Clinical investigations with our lead antibody CAN04 to our proprietary target

Göran Forsberg, CEO



### Safe Harbour Statement

The following presentation may include predictions, estimates or other information that might be considered forward-looking. The statements regarding the surrounding world and future circumstances in this presentation reflect Cantargia's current thinking with respect to future events and financial performance. Prospective statements only express the assessments and assumptions the company makes at the time of the presentation. These statements are wellconsidered, but the audience should note that, as with all prospective assessments, they are associated with risks and uncertainties.



## Cantargia

- Opportunity to save lifes and create value
- Potentially more effective treatment in clinically validated pathway against novel target
- Right team and clear plan to position our projects and maximize value
- First in class platform technology against novel target





#### Major clinical study - validating data

#### CANTOS trial (n=10061)

- Canakinumab (Novartis)
- Reduced lung cancer incidence by 67
  % and death by 77 %.



- Clinical validation of IL-1 pathway
- Dose/response
- Cantargia's CAN04 has broader MOA

Canakinumab phase 3 trials (compl 20121/2022)

Adjuvant NSCLC (CANOPY-A) 1500 patients After surgery, no mets, placebo control

**First line (CANOPY-1)** 627 patients Untreated locally advanced/metastatic Combination Pembro/Platinum doublet

Second line metastatic (CANOPY-2) 240 patients Previously treated loc adv/metastatic Combination Docetaxel

...and Gevokizumab trials in to start:

- Renal cell cancer
- Gastroesophageal cancer
- Colorectal cancer

Source clinicaltrials.gov



## CAN04 (nidanilimab) added value vs canakinumab



### CAN04 – Dual anticancer mechanism





ADCC









## CAN04 – CANFOUR clinical trial

#### Phase I/IIa trial - NSCLC and pancreatic cancer

- Jules Bordet, Brussels; Erasmus Rotterdam, NKI, Amsterdam; Rigshospitalet, Copenhagen; Radiumhospitalet, Oslo
- 22 patients treated:
  - Good safety up to 10 mg/kg
  - Significant effect on relevant biomarkers (IL-6, CRP)
  - 5/13 pts had stable disease up to 6 months
  - NSCLC, pancreatic cancer, colon cancer
- Phase IIa: focused on NSCLC and pancreatic Dose group 1 cancer (appr 20 centres)
  - FPI Jan 2019 Data early 2020
  - Monotherapy (appr 20 pat)
  - Combination with standard therapy (appr 30 pat per arm)
    - NSCLC Cisplatin/Gemcitabine
    - Pancreatic cancer Gemcitabine/nab-paclitaxel



Clinical studies	
Dec 2018	Early 2020

Details on www.clinicaltrials.gov



## CAN04 – CANFOUR clinical trial and next steps



Expansion of most promising subgroup

FDA/EMA advice

Preparations for randomized/pivotal phase

Partnering



## IL1RAP in several cancer with high medical need



- Cantargia founded based on:
  - Discovery of IL1RAP on cancer cells
  - Antibodies against IL1RAP antitumor effects
  - Patents on antibody therapy against IL1RAP
- Primary indications. NSCLC and pancreatic cancer
- Biomarker studies ongoing, identify patients most likely to respond
- Opportunity to expand development in additional cancer forms
- Cantargia has granted patent on antibody therapy against IL1RAP





Two major preclinical findings during 2018 -new opportunities

Binding to immune cells in tumor microenvironment

-Antimetastatic effects

-Counteract immune suppression

Synergisitic effects with chemotherapy

-Stronger antitumor effects

-Counteracts chemotherapy toxicity



### CAN04 counteract metastases

- Cancer cells (seeds) needs a good soil to form a metastasis
- The IL-1 system (inflammation) can provide such environment (soil)
- Data generated in 4T1 (TNBC) model (n=10)





A tumor can create its own "seed and soil"



# Targeting both tumor and endogenous IL1RAP allows synergistic effects with Cisplatin





#### CAN04 attacks several cell types in the tumor



# CANTOS additional findings (from Novartis IL-1β antibody) -identification of additional opportunities

CANCER decreased risk of death with treatment (high dose)				
Lung cancer	77 %	P=0.0002		
Non-lung cancer	37 %	P=0.06		
Decreased incidence of inflammatory disease (all doses)				
Arthritis	32%	p<0.0001		
Ostheoartritis	28%	P=0.0005		
Gout	53%	p<0.0001		
Cardiovascular	12%	P=0.02		
Biomarker levels (reduction)				
CRP	26-41%	P<0.0001		
IL-6	25-43%	P<0.001		



### IL1RAP platform to treat serious diseases

- Three different systems signal through IL1RAP
- These systems contribute to various inflammatory diseases
- Can be blocked by Cantargia's antibodies against IL1RAP



Cantargia partnership with Panorama Res Inc (Sunnyvale, CA) Selection of clinical candidate 2019



#### Significant value inflection points ahead of CANFOUR results

#### 2019

- US regulatory and clinical strategy
- Clinical progress and initial phase IIa results
- Preclinical progress (immuno-oncology effects, combinations etc)
- CANxx progress

#### 2020

• Phase IIa results



# Lead project CAN04 in the highest growth segment– Oncology antibodies



Sales cancer therapeutic antibodies 2017 (2016)

Rituxan/MabThera	\$7.87bn	(\$8.58bn)
Avastin	\$7.13bn	(\$6.75bn)
Herceptin	\$7.47bn	(\$6.75bn)

Source IMS Health & company reported sales

Immuno-oncology driving market growth 2017 (2016)

Opdivo	\$4.95bn	(\$3.77bn)
Keytruda	\$3.81bn	(\$1.40bn)



### Cantargia IP

#### Use of IL1RAP as target for hematological cancers

Valid until 2030

Granted (EPO, USA, Japan, China)

#### Use of IL1RAP as target for solid tumors

Valid until 2032

Granted (EPO, Japan, USA, China)

- The product candidate CAN04
  - Valid until 2035
  - Granted EPO, USA, China

#### New IL1RAP antibodies (e.g. CAN03) Valid until 2035 Granted USA





# Cantargia at a glance

- Specialized in antibody therapy/immunology initial focus on oncology
- Lead antibody CAN04 (nidanilimab) in phase IIa clinical development, pathway clinically validated, data early 2020
- Platform around IL1RAP, lead candidate for autoimmunity and inflammatory disease 2019
- Granted IP therapeutic target IL1RAP and CAN04
- Strong management team with proven track record in clinical development and business development
- Listed on Nasdaq Stockholm
- Approximately 5000 shareholders
- Based in Lund, Sweden

#### **Financial highlights**

- Share price: 15.90 SEK (1.72 USD), Feb 28, 2019
- Market cap: 1052 MSEK (114 MUSD), Feb 28, 2019
- Cash: 167 MSEK (18.1 MUSD), Dec 31, 2018

#### Current owners (Dec 31, 2018)

Sunstone	9.0%
1st AP fund	6.9%
SEB S.A.	5.0%
Avanza Pension	5.0%
4th AP fund	4.6%
Öhman Bank S.A.	4.1%
2nd AP fund	3.3%
Mats Invest AB	2.0%
Tibia konsult	1.9%
Kudu AB	1.9 %
Others	56.3%

